Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis

NCT01865812 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.

NCT NCT01865812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01865812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Lead sponsor
Intercept Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2013
Completion date
September 12, 2016
Enrollment
27 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cirrhosis